This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abdel-Maksoud M, El-Shokry M, Ismail G, Hafez S, El-Kholy A, Attia E, Talaat M. Methicillin-Resistant Staphylococcus aureus recovered from healthcare- and community-associated infections in Egypt. Int J Bacteriol. 2016;2016:1–5. doi:10.1155/2016/5751785 MedlineAbdel-MaksoudMEl-ShokryMIsmailGHafezSEl-KholyAAttiaETalaatM.Methicillin-Resistant Staphylococcus aureus recovered from healthcare- and community-associated infections in EgyptInt J Bacteriol.201620161–5. doi:10.1155/2016/5751785Medline494057727433480Open DOISearch in Google Scholar
Borg MA, de Kraker M, Scicluna E, van de Sande-Bruinsma N, Tiemersma E, Monen J, Grundmann H; ARMed Project Members and Collaborators. Prevalence of methicillin-resistant Staphy lo coccus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother. 2007; 60(6):1310–1315. doi:10.1093/jac/dkm365 MedlineBorgMAde KrakerMSciclunaEvan de Sande-BruinsmaNTiemersmaEMonenJGrundmannH; ARMed Project Members and CollaboratorsPrevalence of methicillin-resistant Staphy lo coccus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countriesJ Antimicrob Chemother.200760(6):1310–1315. doi:10.1093/jac/dkm365Medline17913724Open DOISearch in Google Scholar
CLSI. Methods for determining Bactericidal Activity of Antimicro bial Agents: approved guideline M26-A, 1999. Wayne (USA): Clinical and Laboratory Standards Institute.CLSIMethods for determining Bactericidal Activity of Antimicro bial Agents: approved guideline M26-A1999Wayne (USA)Clinical and Laboratory Standards InstituteSearch in Google Scholar
CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-Ninth Edition M07-A9. 2012. Wayne (USA): Clinical and Laboratory Standards Institute.CLSIMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-Ninth Edition M07-A92012Wayne (USA)Clinical and Laboratory Standards InstituteSearch in Google Scholar
CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. 2013. Wayne (USA): Clinical and Laboratory Standards Institute.CLSIPerformance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S232013Wayne (USA)Clinical and Laboratory Standards InstituteSearch in Google Scholar
Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L519–L528. doi:10.1152/ajplung.00312.2006 MedlineDubinPJKollsJK.IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in miceAm J Physiol Lung Cell Mol Physiol.2007292(2):L519–L528. doi:10.1152/ajplung.00312.2006Medline284197717071720Open DOISearch in Google Scholar
Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP. MRSA in Africa: filling the global map of antimicrobial resistance. PLoS One. 2013;8(7):e68024. doi:10.1371/journal.pone.0068024 MedlineFalagasMEKarageorgopoulosDELeptidisJKorbilaIP.MRSA in Africa: filling the global map of antimicrobial resistancePLoS One.20138(7):e68024. doi:10.1371/journal.pone.0068024Medline372667723922652Open DOISearch in Google Scholar
Fernandes P, Martens E. Antibiotics in late clinical development. Biochem Pharmacol. 2017;133:152–163. doi:10.1016/j.bcp.2016.09.025 MedlineFernandesPMartensE.Antibiotics in late clinical developmentBiochem Pharmacol.2017133152–163. doi:10.1016/j.bcp.2016.09.025Medline27687641Open DOISearch in Google Scholar
Hannachi-M’Zali F, Ambler JE, Taylor CF, Hawkey PM. Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC). J Antimicrob Chemother. 2002;50(5):649–655. doi:10.1093/jac/dkf243 MedlineHannachi-M’ZaliFAmblerJETaylorCFHawkeyPM.Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC)J Antimicrob Chemother.200250(5):649–655. doi:10.1093/jac/dkf243Medline12407120Open DOISearch in Google Scholar
Kaatz GW, Moudgal VV, Seo SM. Identification and charac teriza tion of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother. 2002;50(6):833–838. doi:10.1093/jac/dkf224 MedlineKaatzGWMoudgalVVSeoSM.Identification and charac teriza tion of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureusJ Antimicrob Chemother.200250(6):833–838. doi:10.1093/jac/dkf224Medline12461001Open DOISearch in Google Scholar
Karpiuk I, Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl Epidemiol. 2013;67(3):455–460. MedlineKarpiukITyskiS.Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trialsPrzegl Epidemiol.201367(3):455–460MedlineSearch in Google Scholar
Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15(1):34. doi:10.1186/s12941-016-0150-4 MedlineKocsisBDomokosJSzaboD.Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacinAnn Clin Microbiol Antimicrob.201615(1):34. doi:10.1186/s12941-016-0150-4Medline487806727215369Open DOISearch in Google Scholar
Kocsis B, Szabo D. Zabofloxacin for chronic bronchitis. Drugs Today (Barc). 2016;52(9):495–500. doi:10.1358/dot.2016.52.9.2530595 MedlineKocsisBSzaboD.Zabofloxacin for chronic bronchitisDrugs Today (Barc).201652(9):495–500. doi:10.1358/dot.2016.52.9.2530595Medline27883116Open DOISearch in Google Scholar
Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother. 2006;58(3):684–688. doi:10.1093/jac/dkl304 MedlineKwonARMinYHRyuJMChoiDRShimMJChoiEC.In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agentJ Antimicrob Chemother.200658(3):684–688. doi:10.1093/jac/dkl304Medline16873394Open DOISearch in Google Scholar
Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996;40(10):2321–2326. doi:10.1128/AAC.40.10.2321 MedlinePanXSAmblerJMehtarSFisherLM.Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniaeAntimicrob Agents Chemother.199640(10):2321–2326. doi:10.1128/AAC.40.10.2321Medline1635288891138Open DOISearch in Google Scholar
Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int J Antimicrob Agents. 2010;36(1):97–98. doi:10.1016/j.ijantimicag.2010.02.022 MedlineParkHSJungSJKwakJHChoiDRChoiEC.DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniaeInt J Antimicrob Agents.201036(1):97–98. doi:10.1016/j.ijantimicag.2010.02.022Medline20403681Open DOISearch in Google Scholar
Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother. 2006;50(6):2261–2264. doi:10.1128/AAC.01407-05 MedlineParkHSKimHJSeolMJChoiDRChoiECKwakJH.In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridoneAntimicrob Agents Chemother.200650(6):2261–2264. doi:10.1128/AAC.01407-05Medline147912416723601Open DOISearch in Google Scholar
Park HS, Oh SH, Kim HS, Choi DR, Kwak JH. Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniae. Molecules. 2016;21(11):1562. doi:10.3390/molecules21111562 MedlineParkHSOhSHKimHSChoiDRKwakJH.Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniaeMolecules.201621(11):1562. doi:10.3390/molecules21111562Medline627359027869677Open DOISearch in Google Scholar
Randhawa MA. Calculation of LD50 values from the method of Miller and Tainter, 1944. J Ayub Med Coll Abbottabad. 2009;21(3):184–185. MedlineRandhawaMA.Calculation of LD50 values from the method of Miller and Tainter, 1944J Ayub Med Coll Abbottabad.200921(3):184–185MedlineSearch in Google Scholar
Sadaka SM, El-Ghazzawy EF, Harfoush RA, Meheissen M. Evaluation of different methods for the rapid diagnosis of methi cillin-resistance in Staphylococcus aureus. Afr J Microbiol Res. 2009;3:49–55.SadakaSMEl-GhazzawyEFHarfoushRAMeheissenM.Evaluation of different methods for the rapid diagnosis of methi cillin-resistance in Staphylococcus aureusAfr J Microbiol Res.2009349–55Search in Google Scholar
Sierra JM, Marco F, Ruiz J, Jiménez de Anta MT, Vila J. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus. Clin Microbiol Infect. 2002;8(12):781–790. doi:10.1046/j.1469-0691.2002.00400.x MedlineSierraJMMarcoFRuizJJiménez de AntaMTVilaJ.Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureusClin Microbiol Infect.20028(12):781–790. doi:10.1046/j.1469-0691.2002.00400.xMedline12519351Open DOISearch in Google Scholar
Tokajian S. New epidemiology of Staphylococcus aureus infections in the Middle East. Clin Microbiol Infect. 2014;20(7):624–628. doi:10.1111/1469-0691.12691 MedlineTokajianS.New epidemiology of Staphylococcus aureus infections in the Middle EastClin Microbiol Infect.201420(7):624–628. doi:10.1111/1469-0691.12691Medline24861893Open DOISearch in Google Scholar
Vidaillac C, Guillon J, Arpin C, Forfar-Bares I, Ba BB, Grellet J, Moreau S, Caignard DH, Jarry C, Quentin C. Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(3):831–838. doi:10.1128/AAC.01306-05 MedlineVidaillacCGuillonJArpinCForfar-BaresIBaBBGrelletJMoreauSCaignardDHJarryCQuentinC.Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureusAntimicrob Agents Chemother.200751(3):831–838. doi:10.1128/AAC.01306-05Medline180315617101679Open DOISearch in Google Scholar
Yun HJ, Min YH, Jo YW, Shim MJ, Choi EC. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV. Int J Antimicrob Agents. 2005; 25(4):334–337. doi:10.1016/j.ijantimicag.2004.11.013 MedlineYunHJMinYHJoYWShimMJChoiEC.Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IVInt J Antimicrob Agents.200525(4):334–337. doi:10.1016/j.ijantimicag.2004.11.013Medline15784314Open DOISearch in Google Scholar
, 